Payment overview · 2025
General Payments
$14,564.27
50 reported records · 10 companies
Healthcare provider profile · identity verified
Zeyar Thet, MD
Allopathic & Osteopathic Physicians|General Practice · FLUSHING, NY · NPI 1356429922
Verified facts
What the public records show
CMS Open Payments records show Zeyar Thet, MD received $14,564.27 in general payments during 2025 across 50 reported records.
Gilead Sciences, Inc. accounted for 84.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Biktarvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $12,307.53 | 84.5% | 28 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $1,833.84 | 12.6% | 7 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $95.85 | 0.7% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $75.51 | 0.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.23 | 0.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.87 | 0.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.31 | 0.3% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $39.82 | 0.3% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $24.34 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.97 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,035.00 | 4 |
| Consulting Fee | $1,778.00 | 2 |
| Food and Beverage | $1,476.00 | 41 |
| Travel and Lodging | $273.39 | 2 |
| Education | $1.88 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $5,933.23 | 6 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $5,885.00 | 5 | 2025 |
Source payment records
|
|||||
| S-217622 Normalized: s 217622 |
Drug | Shionogi Inc | $1,580.00 | 1 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $253.84 | 6 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $95.85 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.23 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.87 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $57.87 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.87 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $54.96 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $46.31 | 2 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $39.82 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $39.82 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $20.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 156 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 15 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
156 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 173 | 22 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 156 | 20 |
| Atorvastatin Calcium | Atorvastatin Calcium | 98 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 16 |
| Eliquis | Apixaban | 50 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 44 | 11 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 43 | 20 |
| Gabapentin | Gabapentin | 43 | 12 |
| Metformin Hcl | Metformin Hcl | 43 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 39 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Furosemide | Furosemide | 30 | 16 |
| Isoniazid | Isoniazid | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Jardiance | Empagliflozin | 28 | 15 |
| Rifampin | Rifampin | 27 | suppressed |
| Losartan Potassium | Losartan Potassium | 26 | 14 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 23 | suppressed |
| Lisinopril | Lisinopril | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,564.27 · 50 records | Gilead Sciences, Inc. | ABRYSVO, APRETUDE, Arikayce, Biktarvy, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DOVATO, Descovy, EGRIFTA, Fetroja, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, PENBRAYA, PREVNAR 20, S-217622, TROGARZO, Yeztugo | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error